^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    03/09/2012
    Excerpt:
    Inlyta is indicated for the treatment of adult patients with advanced renal-cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    01/27/2012
    Excerpt:
    INLYTA is a kinase inhibitor indicated:...as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the NCCN panel has included axitinib as a first-line treatment option (category 2B) for use under certain circumstances for patients of all risk groups.